Gene therapy has emerged as a promising approach for the lethal disorder of Duchenne muscular dystrophy (DMD). Using a novel non-viral delivery system, the human ribosomal DNA (hrDNA) targeting vector, we targeted a minidystrophin-GFP fusion gene into the hrDNA locus of HT1080 cells with a high site-specific integrated efficiency of 10
Introduction
Duchenne muscular dystrophy (DMD) is a severe X-linked muscle-wasting disorder caused by mutations in the dystrophin gene, which affects about 1 in 3500 live born males [1, 2] . Dystrophin localized beneath the inner surface of myofiber plasma membrane in both skeletal and cardiac muscles to form the dystrophinassociated protein (DAP) complexes, thereby linking the actin cytoskeleton to the extracellular matrix. The absence of functional DAP complexes leads to chronic muscle damage and degenerative pathology [3] . Currently, gene therapy has emerged as a promising approach for this incurable disorder. The success of gene therapy largely depends on the development of a vector that can efficiently deliver a gene to target cells with minimal toxicity and obtain sustained (if possible, lifelong) expression [4] . Viral vectors are highly efficient at introducing gene into cells; however, their use has been associated with genotoxic effects of vector integration that increase the risk of insertional mutagenesisor, carcinogenesis [5] [6] [7] or immune responses to viral proteins that results in immunologic complications and transient transgene expression [8, 9] .
Compared with viral vectors, non-viral vectors can avoid efficiently the safety troubles outlined above. A plasmid DNA expressing human dystrophin was used in the first gene therapy phase I clinical trial for Duchenne/ Becker muscular dystrophy [10] . A significant drawback of non-viral vector is the lack of chromosomal integration that makes it difficult to obtain sustained transgene expression. To overcome this shortcoming, we developed a novel non-viral vector system, which could integrate an exogenous gene into the human ribosomal DNA (hrDNA) locus, thus obtaining site-specific integration and long-term transgene expression [11] [12] [13] . In the present study, we transfected HT1080 cells with pHrndysG, a hrDNA-targeting vector carrying a minidystrophin-GFP fusion gene to evaluate its potential application in the gene therapy study for DMD.
Material and Methods
Materials hrDNA-targeting vector, pHrndysG, was constructed as described previously [14] . Human fibrosarcoma cells (HT1080) was purchased from ATCC. Plasmid Purification Kit was obtained from QIAGEN (Hilden, Germany). Restriction enzymes were purchased from NEB (Beverly, MA, USA Plasmid preparation, cell culture, electroporation, and selection Plasmid DNA was prepared with QIAGEN Plasmid Maxi kit according to the manufacturer's directions. Human fibrosarcoma cells (HT1080) were cultured in Dulbecco's modified Eagle's medium high glucose (4.5 g/L) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 0.1 mM non-essential amino acids, and 50 U/ml penicillin and 50 mg/ml streptomycin (P/S) (all from Invitrogen) at 378C in a humidified 5% CO 2 atmosphere. On the day prior to transfection, HT 1080 cells were passaged on a subcultivation ratio of 1:3 (approximately 30% confluence) and incubated overnight. For DNA electroporation, HT 1080 cells were collected by trypsinization and 3 Â 10 6 cells were electroporated with pHrndysG plasmid (20 mg DNA) linearized by AhdI in a 0.4-cm cuvette using a BioRad gene pulser (BioRad). The parameters of electroporation were: 2000 kV and 50 mF. After electroporation, the cells were seeded in 100-mm cell culture dishes (BD). Seventy-two hours after transfection, the medium was discarded and replaced by selection medium containing 400 mg/ml G418 (Invitrogen). Selection medium was changed every 3 days. After maintaining the selection of G418 for 12-14 days, five to six G418-resistant clones were picked from each dish and the dishes were then fixed and stained with Giemsa for counting. The selected clones were transferred into 24-well Cell Culture Plates (BD) for expansion of cultivation.
Identification of recombinants by PCR and DNA sequencing Genomic DNA extraction from individual drug-resistant colonies was performed as previously described [12] , briefly involving sodium dodecyl sulfate (SDS) lysis, proteinase K digestion, phenol extraction and ethanol precipitation. The prepared genomic DNA was then screened for correct targeting of the hrDNA locus by PCR amplifying a 1.6-kb fragment. The following primer set was used: screen-rc (5 0 -AAT GGG CGG GGG TCG TTG GGC GGT CA-3 0 ) was located in the cytomegalovirus (CMV) promoter ( Fig. 1) , screen-dn (5 0 -GGC GAT TGA TCG GCA AGC GAC GCT CAG ACA G-3 0 ) was located out of the short homologous arm (SHA) of the hrDNA locus ( Fig. 1) . For positive clones identified by PCR, the PCR amplified products were Figure 1 Scheme of site-specific integration pHrndysG contained two inverted expression cassettes, one consisted of an IRES element from the encephalomyocarditis virus (EI), the coding region of the neo gene (NEO) and SV40 polyA signal (SpA), NEO lacks a promoter, the expression is activated by the promoter of the hrDNA gene after homologous recombination; another was minidystrophin (DR3-R21,CT)-GFP expression cassette, which is activated by a CMV promoter (Pcmv), and contained a BGH polyA signal (BpA) at its end [14] ; LHA, long homologous arm (U13369:937-5467); SHA, short homologous arm (U13369:5468-6523). rDNA HS indicates the 5.6 kb sequence (U13369:937-6523) required for homologous recombination into the 18S rRNA gene [13] . There are one PvuII site in NEO gene and one PvuII site outside of the long homologous sequence, the size of the fragment between the two PvuII is 7230 bp, and it can be detected by probe of EMCV-IRES. Screen-rc was located in the CMV promoter, Screen-dn was located outside of the SHA of the hrDNA locus. The fragment of PCR amplification with Screen-rc and Screen-dn is 1.6 kb.
Non-viral vector for DMD gene therapy reclaimed by ethanol precipitation and then cloned into pGEM-T vector according to the manufacturer's instructions. The PCR fragment was verified by DNA sequencing with primer-T7 (5 0 -TAA TAC GAC TCA CTA TAG GG-3 0 ) and primer-SP6 (5 0 -CAT ACG ATT TAG GTG ACA CTA TAG-3 0 ).
Detection of targeted clones by Southern blotting analysis
Genomic DNA was prepared from the site-specific integration clones identified by PCR. The DNA (20 mg) was subject to overnight digestion by PvuII at 378C, then separated on 1.0% (w/v) agarose, and blotted onto a positively charged nylon membrane (Millipore). The DNA was fixed to the membrane by baking it at 808C for 2 h under vacuum prior to prehybridization for 1 h at 428C in DIG Easy Hyb solution provided in DIG High Prime DNA Labeling System and Detection Starter Kit I. The DNA probe was a 333-bp fragment of EMCV-IRES. Using pHrndysG as a template, the probe was amplified by using emir-up (5 0 -ccc gga aac ctg gcc ctg tct t-3 0 ) and emir-down (5 0 -tgg ggt acc ttc tgg gca tcc ttc-3 0 ), then labeled through mixing it with the DIG-High Prime contained in the kit for 20 h at 378C. Hybridization was performed at 428C for 16 h. After appropriate post-hybridization washes, the membrane was then followed by a 3 min rinse in washing buffer, 30 min successive incubation in both blocking solution and antibody solution with shaking. After appropriate washing in washing solution and equilibration in detection buffer, the membrane was incubated in freshly prepared color substrate solution in the dark for 16 h without shaking, the hybridized probes were immunodetected with anti-digoxigenin-AP conjugate, and visualized with the colorimetric substrates NBT/BCIP. Results were documented by photocopying the wet filter.
Detection of the minidystrophin-GFP expression in site-specific integration clones by RT-PCR and western blotting PCR-positive clones without random integration into the genome identified by southern blotting analysis were chosen for the detection of minidystrophin-GFP expression. And these same clones that underwent longterm culture by passage were also detected to confirm the continuous expression of transgene. Total RNA was purified with Trizol reagent (Invitrogen). One microgram of total RNA was used for reverse transcription reaction with Reverse Transcription System (Promega) and Oligo(dT 15 ) Primer, according to the manufacturer's instructions. Then minidystrophin-GFP cDNA was detected by PCR amplifying a 750-bp fragment with primer tdcf (5 0 -ACG GTA CCA CTC ATA GAT TAC TGC AAC AGT TC-3 0 ) and primer tdcr (5 0 -GGG GTA CCC TCA TCT ATT TTT CTC TGC CAG TC-3 0 ). The fusion gene expression of those clones analyzed by RT-PCR was further detected by western blotting. Cells to be detected were seeded in 6-well Cell Culture Plates (BD). When cells showed 80% confluency, the medium was discarded and the cells were washed once with phosphate-buffered saline (PBS), dissolved in 200 ml of 2Â sample buffer plus a cocktail of protease inhibitors (Roche). Next, the lysates were heated for 10 min at 1008C and were separated by 5% SDS-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride (Millipore) by electroblotting. After incubation for 1 h at room temperature with blocking solution (5% non-fat dry milk in TBS-Tween), the membrane was incubated overnight at 48C with monoclonal antibody anti-dystrophin diluted 1:50 in blocking solution, a monoclonal antibody recognizing an epitope in the N-terminal domain of dystrophin. After appropriate washing, membranes were incubated with horseradish peroxidase (HRP)-conjugated antimouse IgG. Chemiluminescent signals were detected by autoradiography using the ECL System (Amersham, Piscataway, NJ, USA).
Identification of the intracellular distribution of minidystrophin-GFP fusion protein by immunocytochemistry For judgment of the intracellular distribution of minidystrophin-GFP fusion protein in site-specific integration clones of HT1080, we transfected HT1080 cells with pEGFP-N1 by lipofection as a negative control. Lipofection was performed according to the manufacturer's instruction of Lipofectamine 2000 reagent (Invitrogen). Coverslips were placed in the 24-well Cell Culture Plates before cell seeding. For immunocytochemistry, cells were rinsed three times with PBS, then fixed with PBS containing 4% paraformaldehyde for 20 min at room temperature. After washing three times with PBS, the cells were blocked for 60 min at room temperature with blocking solution (3% BSA in PBS containing 0.1% Triton-X), then incubated with primary antibody (anti-dystrophin diluted 1:50 in blocking solution) for 1 h. After appropriate washing, the cells were incubated with Cy3-conjugated goat anti-mouse IgG (Chemicon) (1:500) at room temperature for 2 h in the dark. The cells were rinsed three times with PBS, and Non-viral vector for DMD gene therapy diluted DAPI to 300 ng/ml in PBST (PBS containing 0.1% Triton-X). The cells were then incubated for 2 min in the diluted DAPI to stain nuclei. After appropriate washing, coverslips were mounted on microscopic slides and the immunolabeled cells were observed under the laser scanning confocal microscope (Leica).
Results

Identification of site-specific integration clones
In the case of site-specific integration, a specific fragment of 1.6 kb could be amplified by PCR with screen-rc and screen-dn (Fig. 1) . Figure 2 shows the expected fragment of 1.6 kb amplified from the sitespecific integrated clone, which was confirmed by DNA sequencing (data not shown) and indicated that the minidystrophin-GFP fusion gene expression cassette carried by pHrndysG was targeted into the hrDNA locus of HT1080 cells.
Efficiency of site-specific integration
In the present study, we transfected 3 Â 10 6 HT1080 cells with 20 mg linearized pHrndysG plasmid twice by electroporation and obtained 1134 and 982 G418-resistant clones, respectively. We selected randomly 104 and 110 of these clones for screening for correct targeting to the locus, 11 and 22 of them were detected to be site-specific integration clones by PCR. The efficiency of site-specific integration was 4 Â 10 25 and 6.5 Â 10
25
, respectively.
Southern blotting analysis of recombinants
Four positive clones identified by PCR were chosen randomly for southern blotting analysis. All these PCR-positive clones showed the 7.2 kb recombinant band (Fig. 3) , but one clone showed two bands smaller than 7.2 kb (Fig. 3, lane 2) except the recombinant one, indicating two random integrations into the genome. Those site-specific integration clones without random integration were chosen for further studies.
Efficient transcription of transgene were detected by RT-PCR
The RNA extracted from site-specific integration clones were used as template for reverse transcription and PCR. Primers tdcf and tdcr span four introns (55-58) of dystrophin. The expected fragment of 750 bp was amplified in positive clones after long-term culture (Fig. 4) as Non-viral vector for DMD gene therapy detected after short-term culture (data not shown), indicating that the minidystrophin-GFP fusion gene could efficiently and continuously express in the site-specific integration clones of HT1080 cells after long-term culture in vitro. This is consistent with both that CMV promoter is one of the most powerful RNA polymerase II (Pol II) promoters and that rDNA is an active region of transcription.
Western blotting detected the interest protein expression The molecular weight of minidystrophin-GFP fusion protein is 174 kD. We detected a band of 174 kD in sitespecific integration clones after long-term culture with anti-dystrophin (Fig. 5) as detected initially (data not shown), but none in HT1080 cells, indicating that the integrity fusion protein was expressed correctly and continuously.
Minidystrophin-GFP fusion protein tended to localize on the plasma membrane of HT1080 cells It was observed that green fluorescence dispersed in the entire cell after lipofection of pEGFP-N1 in HT1080 cells [ Fig. 6(C,D) ]; however the green fluorescence of pHrndysG tended to localize on the plasma membrane of site-specific integration clones of HT1080 [ Fig. 6(A) ], which was further confirmed by immunofluorescence [ Fig. 6(B) ]. The results suggested that the fusion of eGFP to minidystrophin does not interfere with the normal localization of the protein and might perform the physiologic function.
Discussion
For monogenic inherited diseases, gene therapy strategies generally include gene reparation and gene augmentation. Gene reparation is the ideal method by accurate correction of the faulty gene using gene targeting [15] . Gene reparation is not suitable for DMD gene therapy because of the complexity and diversity of dystrophin gene mutation or deletion. In contrast to gene reparation, gene augmentation strategy, i.e. adding a functional or therapeutic gene to compensate the function of faulty gene, would be applicable to the treatment of any type of DMD. Viral vectors were widely used in the gene augmentation for DMD gene therapy [16] [17] [18] [19] , but their safety has always been a concern. For gene augmentation by non-viral gene targeting, moreover, its low integration efficiency of 10 26 -10 28 in mammalian cells [20, 21] has been a major limitation to its application. We applied a novel non-viral vector system to gene therapy study of DMD by targeting a minidystrophin-GFP fusion gene into the hrDNA locus of HT1080 cells. A higher targeting efficiency (10 25 order) was obtained in the present study than that obtained by using other targeting vectors in HT1080 cells (10 26 order) [22, 23] , and similar targeting efficiency was obtained in human hepatocyte cells using the hrDNA-targeting vector in our previous study [12] , which may be attributed to the enrichment strategy of 'promoter-trap' selection [11, 12] , high copy number of rDNA locus, and homologous recombination hotspot at the target site. The researches on yeast and Arabidopsis thaliana cells suggested that rDNA region has some function components to stimulate the occurrence of homologous recombination [24] . The rDNA structures of most eukaryotic cells including human cells are very similar [25] , therefore, rDNA region as a homologous recombination hotspots may be a common phenomenon in the majority eukaryotic cells including human cells. In addition, for the safety concern, targeting an exogenous gene into one or a few ribosomal RNA (rRNA) gene locus may be allowed without deleterious effects owing to its high copy number.
To avoid the inconvenience in manipulating a large size of dystrophin cDNA in gene therapy, much research has been conducted to engineer a minidystrophin gene, which expresses a truncated but functional protein.
These miniproteins tend to have common deletions of the central rod domain and carboxy terminus leaving vital binding domains intact [18, 19, 26] . The minidystrophin (DR3-R21,CT) constructed as described previously [27] has been proved to be functional in mdx mice, including anchoring to the plasma membrane, restoration of DAP complexes, protection of myofiber membrane integrity, amelioration of dystrophic pathology [27] , and improvement of dystrophic muscle contractile function [28] . In myogenic cells, the cysteine-rich domain of dystrophin interacts with b-dystroglycan, a transmembrane protein not restricted to muscle but widely expressed in most human cells [29] . In the present study, we found that the minidystrophin (DR3-R21,CT)-GFP fusion protein tended to localize on the plasma membrane of site-specific integration clones of HT1080 cells, indicating the fusion of eGFP to minidystrophin did not interfere with the normal localization of the fusion protein.
Chapdelaine et al. [30] fused an eGFP gene with the N-terminal of mini-and full-length dystrophin, and found the fusion proteins correctly localized on the sarcolemma of myofibers. Li et al. [31] constructed a minidystrophin-GFP fusion gene by C-terminal fusion and found the fusion protein was functional and detectable on the sarcolemma of skeletal myofibers of the transgenic mice. When these transgenic mice were used as donors for transplantation studies, the green minidystrophin-GFP þ myofibers were detected in skeletal muscles of the recipients. Therefore, the minidystrophin-GFP fusion protein encoded by the fuse gene in pHrndysG may be functional. Moreover, eGFP as a marker can be used to trace minidystrophin expression and the distribution of genetically modified cells, which would be especially useful for developing stem cell-based ex vivo gene therapy for DMD.
Obviously, the DMD gene therapy by in vivo gene targeting using non-viral targeting vectors is not the optimized approach due to its relatively low efficiency. Targeting autologous stem cells in culture for ex vivo strategy might be a better choice [32] . The induced pluripotent stem (iPS) cells generated from somatic cells by the ectopic expression of some transcription factors provide tremendous therapeutic potential [33, 34] . Some adult stem cells such as marrow stromal cells (MSCs) can shift to muscle via the vascular system and differentiate into muscle cells [35] . Therefore, it is feasible to target iPS cells and MSCs with pHrndysG further in ex vivo gene therapy study for DMD.
In summary, pHrndysG has successfully targeted a minidystrophin-GFP fusion gene into the hrDNA locus of HT1080 cells with higher efficiency, and the 
